Indivior To Pay Over 100% Premium To Buy Opioid Focused Player Opiant Pharmaceuticals

Vandana Singh
1 min read
0
In this article:

  • Indivior PLC (OTC: INVVY) has agreed to acquire Opiant Pharmaceuticals Inc (NASDAQ: OPNT) for $20.00 per share in cash, plus contingent value rights (CVRs) of up to $8.00 per share.

  • Achievement of the CVR payments, if any, is based on attaining certain revenue thresholds for OPNT003, nasal nalmefene, and Opiant's investigational treatment for opioid overdose.

  • Completion of rolling New Drug Application (NDA) submission for OPNT003 is on track for Q4 2022.

  • The upfront payment of $20.00 per share represents a premium of approximately 111% to Opiant's closing share price on November 11.

  • Inclusive of each CVR payment, the total potential transaction value represents a premium of up to 195%.

  • Pending approvals, the parties anticipate completing the transaction in the first quarter of 2023.

  • Opiant entered a settlement with Emergent Biosolutions Inc (NYSE: EBS), resolving a legal dispute over its royalty obligations to Opiant for NARCAN Nasal Spray.

  • Under the settlement, EBS will make a one-time cash payment of $25 million to Opiant to terminate its license agreement with Opiant.

  • Related: Opiant Pharma Secures Additional BARDA Funding For Opioid Overdose Treatment.

  • For Q3, Opiant recorded $0.2 million of revenue, compared to $16.3 million a year ago, primarily from a contract with the Biomedical Advanced Research and Development Authority. Opiant recorded no royalty revenue from its license agreement with EBS.

  • Opiant had approximately $35.4 million in cash and cash equivalents as of September 30.

  • Price Action: OPNT shares are up 116.80% at $20.60 during the premarket session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories